Patent Application: Diabetes Prevention/Treatment by Myeloid Suppressor Cell Activity

ChangeBridge: Patent Apps - Biotech (C12N)

Detected March 27th, 2026

Summary

The USPTO has published a new patent application (US20260085291A1) from CREATIVE MEDICAL TECHNOLOGIES, INC. The application details methods and compositions for preventing or treating Type 1 diabetes by augmenting myeloid suppressor cell activity, potentially involving conditioned immune cells or exogenous suppressor cells.

View original document View source feed page

What changed

This document is a published patent application from the USPTO, not a regulatory rule or guidance. It describes a novel approach to preventing or treating Type 1 diabetes by modulating myeloid suppressor cell activity. The proposed methods involve administering immune cells conditioned by exposure to regenerative cells (such as umbilical cord-derived mesenchymal stem cells) or cultured in their presence, potentially combined with agents that enhance myeloid suppressor cell activity or with exogenous suppressor cells.

As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it signals potential future developments in diabetes treatment and related biotechnologies. Companies in the pharmaceutical and biotechnology sectors, particularly those involved in cell therapy or autoimmune disease research, should monitor the progress of this and similar patent applications as they may indicate emerging therapeutic areas or intellectual property landscapes.

Source document (simplified)

← USPTO Patent Applications

PREVENTION AND/OR TREATMENT OF TYPE 1 DIABETES BY AUGMENTATION OF MYELOID SUPPRESSOR CELL ACTIVITY

Application US20260085291A1 Kind: A1 Mar 26, 2026

Assignee

CREATIVE MEDICAL TECHNOLOGIES, INC.

Inventors

Thomas Ichim, Amit Patel

Abstract

Disclosed are means, methods and compositions of matter useful for prevention and/or reversion of type 1 diabetes by upregulation of myeloid suppressor cell activity in a mammal suffering from and/or at risk of developing type 1 diabetes. In one embodiment the invention teaches administration of immune cells that have been conditioned by exposure to regenerative cells, and/or cultured in the presence of factors produced from regenerative cells. In one embodiment said regenerative cells are umbilical cord derived mesenchymal stem cells. In one embodiment, immune cells that have been exposed to said regenerative cells are administered together with agents known to enhance myeloid suppressor cell activity. In another embodiment immune cells are administered together with exogenous myeloid suppressor cells. 2